PTC THERAPEUTICS, INC. 8-K

What Happened

• On June 18, 2026, PTC Therapeutics, Inc. completed a private offering of $550,000,000 aggregate principal amount of 0.0% Convertible Senior Notes due 2031 and entered into an indenture with U.S. Bank Trust Company as trustee. The notes were sold under a June 15, 2026 purchase agreement led by Morgan Stanley & Co. LLC; the initial purchasers exercised their full $50.0M option.
• The Notes bear no regular interest (principal does not accrete) but may incur special interest under certain circumstances (payable semiannually beginning Dec 15, 2026 if triggered). Initial conversion rate: 9.3042 shares of common stock per $1,000 principal (≈ $107.48 per share). Notes mature June 15, 2031 and are senior unsecured obligations.
• PTC estimates net proceeds of approximately $535.5 million and is using ~$328.8 million of those proceeds to repurchase $222.0 million principal amount of its existing 1.50% Convertible Senior Notes due 2026 via privately negotiated transactions; after these repurchases, remaining Existing Convertible Notes would total $55.5 million.

Key Details

• Offering size: $550,000,000 (includes full exercise of $50M option).
• Conversion: 9.3042 shares / $1,000 principal (initial conversion price ≈ $107.48/share).
• Use of proceeds: ~$328.8M to repurchase $222.0M of existing convertible notes; net proceeds ≈ $535.5M.
• Important dates: Indenture and offering completed June 18, 2026; notes mature June 15, 2031; company cannot redeem notes before June 20, 2029 (redeemable thereafter if stock price ≥130% of conversion price over specified period).

Why It Matters

• Capital and interest profile: The new 0.0% convertible notes reduce regular cash interest burden versus interest‑bearing debt but introduce potential equity dilution if converted; conversion is subject to specified stock‑price and other conditions (and becomes freely convertible in the final two months before maturity).
• Liability ranking and flexibility: The Notes are general unsecured senior obligations (equal to other unsecured debt, junior to secured debt, and structurally junior to subsidiary liabilities). PTC gains near‑term cash to retire most of its higher‑coupon 2026 convertible notes, lowering near‑term debt obligations.
• Investor impacts: Shareholders should watch potential dilution if conversions occur and monitor company reporting/stock trading conditions that could trigger conversions or special interest. The repurchase reduces immediate outstanding convertible principal, but the new notes extend debt maturity to 2031.